<DOC>
	<DOCNO>NCT02192424</DOCNO>
	<brief_summary>Type 2 diabetes mellitus chronic metabolic disorder characterize progressive deterioration function pancreatic beta-cells , cell produce secrete insulin ( hormone primarily responsible handle glucose body ) . The investigator propose randomize controlled trial determine whether intermittent intensive insulin therapy effective therapeutic strategy preserve pancreatic beta-cell function maintain glycemic control early course type 2 diabetes .</brief_summary>
	<brief_title>Early Intermittent Intensive Insulin Therapy Effective Treatment Type 2 Diabetes ( RESET-IT Main Trial )</brief_title>
	<detailed_description>In study , eligible patient type 2 diabetes randomize either intermittent insulin therapy , background metformin , first undergo short course intensive insulin therapy . The hypothesis study whether intermittent insulin therapy preserve beta-cell function .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Men woman age 30 80 year inclusive 2 . T2DM diagnose physician &lt; /= 5 year prior enrolment 3 . Negative antiglutamic acid decarboxylase ( antiGAD ) antibodies 4 . On either antidiabetic medication metformin monotherapy , change dose/regimen within 4 week prior enrolment 5 . A1c screen 5.5 % 9.0 % inclusive metformin , 6.0 % 9.5 % inclusive oral antidiabetic medication 6 . BMI &gt; /= 23 kg/m2 7 . Negative pregnancy test recruitment woman childbearing potential 1 . Current antidiabetic treatment insulin , sulfonylurea , thiazolidinedione , alphaglucosidase inhibitor , glucagonlike peptide1 ( GLP1 ) agonist dipeptidyl peptidase4 inhibitor 2 . Type 1 diabetes secondary form diabetes 3 . History hypoglycemia unawareness severe hypoglycemia require assistance 4 . Any major illness life expectancy &lt; 5 year 5 . Hypersensitivity insulin , metformin formulation product 6 . Renal dysfunction evidence estimate glomerular filtration rate ( eGFR ) &lt; 50 ml/min 7 . Hepatic disease consider clinically significant ( include jaundice , chronic hepatitis , previous liver transplant ) transaminases &gt; 2.5 X upper limit normal 8 . History congestive heart failure 9 . Excessive alcohol consumption , define &gt; 14 alcoholic drink per week male &gt; 9 alcoholic drink per week female 10 . Unwillingness administer insulin therapy perform capillary blood glucose monitoring least 4 time per day receive IIT 11 . Pregnancy unwillingness use reliable contraception . Women plan pregnancy duration study first 3 month study . Reliable contraception include birth control pill , intrauterine device , abstinence , tubal ligation , partner vasectomy , condom spermicide . 12 . Nonadherence induction phase factor likely limit adherence study protocol , opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>beta-cell function ,</keyword>
	<keyword>type 2 diabetes ,</keyword>
	<keyword>intermittent insulin</keyword>
</DOC>